To, BSE Limited P.J.Towers, Dalal Street Mumbai-400001

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Date: 04.03.2021

Unit: Concord Drugs Limited

I, Nagi Reddy Seelam, Promoter of the company have bought 84,145 Equity Shares. In this regard, I enclose herewith prescribed Form 29 (2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

Nagi Reddy Seelam

Encl: As above.

CC to:Concord Drugs Limited Survey No.249, Brahmanapally Village, Hayatnagar Mandal R.R.District – 501511, Telangana

<u>Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

1.	Name of the Target Company (TC)	Concord Drugs Limited			
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Nagi Reedy Seelam			
3.	Whether the acquirer belongs to Promoter/Promoter group	Yes			
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited			
5.	Details of the acquisition / disposal/holding of shares/voting rights/holding of the Acquirer and PAC	Number	% w.r.t. total share/voti ng capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC(*)	
Be of	efore the acquisition of shares, holding				
	a) Shares carrying voting rights	17,58,395	20.11	20.11	
	b) Voting rights (VR) otherwise than by shares	_	-	-	
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	-	_	
Total (a+b+c)		17,58,395	20.11	20.11	
De	etails of acquisition of shares				
	a) Shares carrying voting rights acquired	84,145	0.96	0.96	
	b) VRs acquired /sold otherwise than by shares	-	-	_	
	c) Warrants/convertible securities/any other instrument				

that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
Total (a+b+c)	84,145	0.96	0.96
After the acquisition of shares, holding of:			
a) Shares carrying voting rights	18,42,540	21.07	21.07
b) VRs otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.	-	-	_
Total (a+b+c)	18,42,540	21.07	21.07
6. Mode of sale (e.g. open market / offmarket / public issue / rights issue / preferential allotment / inter-se transfer etc).	Purchase (on market)		
7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	02.03.2021-03.03.2021		
8. Equity share capital / total voting capital of the TC before the said acquisition / sale	87,43,750 equity shares		
9. Equity share capital/ total voting capital of the TC after the said acquisition / sale	87,43,750 equity shares		
10. Total diluted share/voting capital of the TC after the said acquisition/sale.	87,43,750 equity shares		

^(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.